Use of paclitaxel in patients with pre-existing cardiomyopathy: A review of our experience

International Journal of Cancer

Volumn 93, Issue 1, 2001, Pages 139-141

  Gollerkeri, Ashwin ^a,b   Harrold, Laurie ^a,b   Rose, Michal ^a,b   Jain, Diwaker ^a,b   Burtness, Barbara Ann ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

Anthracycline; Breast cancer; Cardiomyopathy; Congestive; Heart failure; Paclitaxel

Indexed keywords

DOXORUBICIN; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER; CANCER CENTER; CARDIOMYOPATHY; CLINICAL ARTICLE; DRUG EFFECT; DRUG SAFETY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; UNITED STATES;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARDIOMYOPATHIES; DOXORUBICIN; FEMALE; HUMANS; HYPERTENSION; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; RETROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 0035399589     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1295     Document Type: Article

References (21)

1. Taxol: A novel investigational antineoplastic agent
2. Drug therapy: Paclitaxel (Taxol)
3. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer
4. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial therapy for metastatic breast cancer
5. Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute treatment referral center trial
6. Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response
7. Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines
8. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
9. Adjuvant systemic therapy of primary breast cancer
10. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: What do we know in the mid-nineties?
11. Cardiotoxicity of doxorubicin and other anthracycline derivatives
12. Clinical trials in cancer
13. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer
14. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
15. Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors
16. A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells
17. Collection of circulating progenitor cells after epirubicin, paclitaxel and filgastrim in patients with metastatic breast cancer
18. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor
19. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses
20. Cyclophosphamide cardiotoxicity in bone marrow transplantation: A prospective evaluation of new dosing regimens
21. The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function